rs4341 — ACE I/D tag SNP

ACE I/D — The Endurance–Power Dial

The angiotensin-converting enzyme¹¹ angiotensin-converting enzyme
ACE cleaves angiotensin I into angiotensin II (a potent vasoconstrictor) and inactivates bradykinin (a vasodilator). It sits at the centre of the renin-angiotensin-aldosterone system (RAAS) governing blood pressure, fluid balance, and vascular tone gene is home to one of the most studied variants in the history of exercise genetics. The ACE insertion/deletion (I/D) polymorphism — a 287-base-pair Alu repeat sequence in intron 16 — determines circulating and tissue ACE activity in a dose-dependent manner: the D allele drives ACE levels up, the I allele keeps them down. Because standard short-read sequencing arrays cannot reliably genotype this structural variant directly, rs4341 serves as its practical proxy. rs4341 is an intronic C/G SNP in near-complete linkage disequilibrium with the I/D locus: the C allele tags the insertion, and the G allele tags the deletion.

This SNP has been studied in elite mountaineers, endurance runners, rowers, triathletes, sprint athletes, and strength trainers across dozens of populations. The picture that emerges is not a single "athletic gene" but a genuine biological dial — turned one way for aerobic efficiency and endurance, turned the other for power output and strength adaptation.

The Mechanism

ACE sits at a critical enzymatic crossroads. When the D allele is present — particularly in homozygous form (GG at rs4341) — ACE activity is elevated in both serum and skeletal muscle tissue. The consequence is higher circulating angiotensin II²² higher circulating angiotensin II
Angiotensin II is a potent vasoconstrictor that also promotes protein synthesis and cardiac hypertrophy via AT1 receptor signalling, making it anabolic for skeletal muscle under conditions of resistance training, which promotes vasoconstriction and skeletal muscle protein synthesis, and accelerated bradykinin degradation³³ accelerated bradykinin degradation
Bradykinin is a vasodilator that also activates nitric oxide synthase and promotes glucose uptake; its half-life is sharply reduced by elevated ACE activity, which reduces vasodilation and nitric oxide-mediated signalling.

The I allele (C at rs4341) does the opposite: lower ACE activity means less angiotensin II production and prolonged bradykinin half-life. Bradykinin signals through B2 receptors⁴⁴ B2 receptors
B2 bradykinin receptors activate phospholipase C and nitric oxide synthase, improving glucose uptake in skeletal muscle and promoting vasodilation during sustained exercise to promote nitric oxide synthesis, vasodilation, improved glucose uptake in working muscle, and greater mitochondrial efficiency — all traits that support sustained aerobic output.

The Evidence

The foundational evidence comes from decades of athlete cohort studies, capped by two major meta-analyses. A 2022 meta-analysis of 26 studies⁵⁵ 2022 meta-analysis of 26 studies
Ipekoglu G et al. A meta-analysis on the association of ACE and PPARA gene variants and endurance athletic status. J Sports Med Phys Fitness, 2022 covering 2,979 endurance athletes and 10,048 controls found the II genotype (CC at rs4341) significantly enriched among endurance athletes at OR=1.48. A complementary systematic review and meta-analysis of ACE and ACTN3 studies⁶⁶ systematic review and meta-analysis of ACE and ACTN3 studies
Ma F et al. The association of sport performance with ACE and ACTN3 genetic polymorphisms: a systematic review and meta-analysis. PLoS One, 2013 found II genotype at OR=1.35 (95% CI 1.17–1.55) for endurance athlete status, while D allele carriers showed advantages in strength- and power-based events.

The altitude evidence is particularly striking. A study of 141 mountaineers⁷⁷ study of 141 mountaineers
Thompson J et al. Angiotensin-converting enzyme genotype and successful ascent to extreme high altitude. High Alt Med Biol, 2007 attempting peaks above 8,000 metres found the I allele strongly enriched in those who successfully summited — the II group averaged maximum altitudes of 8,559 m versus 8,079 m for DD, a difference of nearly 500 vertical metres. This likely reflects greater aerobic efficiency under hypoxia rather than VO2max per se.

A training study of 58 army recruits⁸⁸ training study of 58 army recruits
Woods DR et al. Endurance enhancement related to the human ACE I-D polymorphism is not due to differences in the cardiorespiratory response to training. Eur J Appl Physiol, 2002 homozygous for either allele found that II subjects showed significantly greater reductions in submaximal oxygen consumption at 80W after training, suggesting the I allele's advantage lies in metabolic efficiency — doing the same work for less oxygen — rather than a simple increase in peak VO2max.

For the D allele, evidence points toward strength adaptation. A 12-year review of ACE exercise genetics⁹⁹ 12-year review of ACE exercise genetics
Puthucheary Z et al. The ACE gene and human performance: 12 years on. Sports Medicine, 2011 noted that the D allele is associated with greater left ventricular mass increases in response to endurance training, larger strength gains in resistance training programs, and enrichment among elite swimmers and short-distance sprinters in several national athlete cohorts.

Practical Implications

This SNP does not determine athletic destiny — elite endurance athletes and elite power athletes carry every genotype. But it does represent a genuine biological tendency that can inform training priorities:

• If you carry CC (II): your aerobic machinery is biased toward efficiency. Sustained efforts — long runs, cycling, rowing, altitude sports — align well with your physiology. Your training response may favour volume over intensity, and altitude camps may bring above-average adaptation.
• If you carry GG (DD): your RAAS is tuned for higher outputs of angiotensin II. Resistance training tends to produce larger strength gains, and explosive, power-based activities play to your physiological tendencies. Cardiovascular monitoring is worth discussing with a physician, since the D allele is linked to higher cardiovascular disease risk in non-athletic contexts.
• If you carry CG (ID): you have the intermediate phenotype — one of each allele, with intermediate ACE activity. Most people carry this genotype. You have genuine versatility without a strong pull in either direction.

Interactions

The ACE I/D has been studied in combination with ACTN3 R577X (rs1815739)¹⁰¹⁰ ACTN3 R577X (rs1815739) in multiple athlete cohorts. The combination of ACE II (CC) with ACTN3 XX (TT) appears to compound endurance advantages, while ACE DD (GG) with ACTN3 RR (CC) compounds power/sprint tendencies. These are observational associations without interventional confirmation but represent the best-studied two-locus interaction in exercise genetics.

ACE activity also interacts with AGTR1 A1166C (rs5186)¹¹¹¹ AGTR1 A1166C (rs5186) — the angiotensin II type 1 receptor variant. Individuals with both elevated ACE activity (D allele) and a more responsive AT1 receptor (C allele) may have amplified angiotensin II signalling, relevant to cardiovascular risk assessment and potentially to training-induced cardiac remodelling.

The MCT1 A1470T (rs1049434)¹²¹² MCT1 A1470T (rs1049434) variant in the lactate transporter gene is a functionally independent but thematically related fitness SNP — lactate clearance complements aerobic capacity in determining sustained high-intensity performance.